-
-
Despite the important progress that has been made in obstetrics, in general, over the last 20 years, shoulder dystocia remains an enigma. Given the rising rate of maternal obesity and gestational diabetes, it is unlikely that the rate of this dangerous complication will be lowered in the near future.
-
Ova-301 was a large (n = 672), open-label phase III trial comparing pegylated liposomal doxorubicin (PLD) to combination PLD and trabectedin (PT) in women with recurrent ovarian cancer. The trial's overall population was previously reported and demonstrated a significant impact on PFS, without a significant improvement in OS.
-
In this issue: Escitalopram for menopausal hot flashes, rifaximin for IBS without constipation, herpes zoster vaccination, antiepileptics drugs and fracture risk, and FDA Actions.
-
Obesity is a growing problem in the united states. the pun would be funny were it not for the adverse influence that the obesity epidemic has had on health care outcomes.
-
Recent investigation into the molecular pathogenesis of epithelial ovarian cancer has implicated two dominant phenotypes.
-
Although the relationship between intrauterine infection and preterm labor (PTL) has been addressed in previous OB/GYN Clinical Alerts, I cannot pass up the opportunity to review a recent paper that sheds new light on a rational approach to PTL.
-
Add new information in your counseling dialogue regarding the human papillomavirus (HPV) vaccine Gardasil.
-
Can same pre-exposure prophylaxis results be recreated in real life?
-
Among the seemingly countless provisions in the March 2010 health reform law is one that greatly simplifies the process by which a state may extend Medicaid eligibility for family planning services and supplies to individuals ineligible for comprehensive health coverage under the program.